Literature DB >> 6189937

Expression of passively transferred immunity against an established tumor depends on generation of cytolytic T cells in recipient. Inhibition by suppressor T cells.

C D Mills, R J North.   

Abstract

The results of this study with the P815 mastocytoma confirm the results of previous studies that showed that the passive transfer of tumor-sensitized T cells from immunized donors can cause the regression of tumors growing in T cell-deficient (TXB) recipients, but not in normal recipients. The key additional finding was that the expression of adoptive immunity against tumors growing in TXB recipients is immediately preceded by a substantial production of cytolytic T cells in the recipients' draining lymph node. On the other hand, failure of adoptive immunity to be expressed against tumors growing in normal recipients was associated with a cytolytic T cell response of much lower magnitude, and a similar low magnitude response was generated in TXB recipients infused with normal spleen cells and in tumor-bearing control mice. Because the passively transferred sensitized T cells possessed no cytolytic activity of their own, the results indicate that the 6-8-d delay before adoptive immunity is expressed represents the time needed for passively transferred helper or memory T cells to give rise to a cytolytic T cell response of sufficient magnitude to destroy the recipient's tumor. In support of this interpretation was the additional finding that inhibition of the expression of adoptive immunity by the passive transfer of suppressor T cells from tumor-bearing donors was associated with a substantially reduced cytolytic T cell response in the recipient's draining lymph node. The results serve to illustrate that interpretation of the results of adoptive immunization experiments requires a knowledge of the events that take place in the adoptively immunized recipient. They support the interpretation that suppressor T cells function in this model to "down-regulate" the production of cytolytic effector T cells.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6189937      PMCID: PMC2187010          DOI: 10.1084/jem.157.5.1448

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  25 in total

Review 1.  Xenogeneic monoclonal antibodies to mouse lymphoid differentiation antigens.

Authors:  J A Ledbetter; L A Herzenberg
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

2.  Quantitative assessment of cellular and humoral responses to skin and tumor allografts.

Authors:  T G Canty; J R Wunderlich
Journal:  Transplantation       Date:  1971-02       Impact factor: 4.939

3.  T-cell-derived helper factor allows in vivo induction of cytotoxic T cells in nu/nu mice.

Authors:  H Wagner; C Hardt; K Heeg; M Röllinghoff; K Pfizenmaier
Journal:  Nature       Date:  1980-03-20       Impact factor: 49.962

Review 4.  Cell-mediated cytotoxicity, allograft rejection, and tumor immunity.

Authors:  J C Cerottini; K T Brunner
Journal:  Adv Immunol       Date:  1974       Impact factor: 3.543

5.  T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor.

Authors:  M J Berendt; R J North
Journal:  J Exp Med       Date:  1980-01-01       Impact factor: 14.307

6.  Cytotoxic T cells: Lyt phenotype and blocking of killing activity by Lyt antisera.

Authors:  E Nakayama; H Shiku; E Stockert; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1979-04       Impact factor: 11.205

7.  Functional subclasses of T-lymphocytes bearing different Ly antigens. I. The generation of functionally distinct T-cell subclasses is a differentiative process independent of antigen.

Authors:  H Cantor; E A Boyse
Journal:  J Exp Med       Date:  1975-06-01       Impact factor: 14.307

8.  The immunological basis of endotoxin-induced tumor regression. Requirement for T-cell-mediated immunity.

Authors:  M J Berendt; R J North; D P Kirstein
Journal:  J Exp Med       Date:  1978-12-01       Impact factor: 14.307

9.  Expression of T-cell differentiation antigens on effector cells in cell-mediated cytotoxicity in vitro. Evidence for functional heterogeneity related to the surface phenotype of T cells.

Authors:  H Shiku; P Kisielow; M A Bean; T Takahashi; E A Boyse; H F Oettgen; L J Old
Journal:  J Exp Med       Date:  1975-01-01       Impact factor: 14.307

10.  The in vitro generation and sustained culture of nude mouse cytolytic T-lymphocytes.

Authors:  S Gillis; N A Union; P E Baker; K A Smith
Journal:  J Exp Med       Date:  1979-06-01       Impact factor: 14.307

View more
  46 in total

Review 1.  Genetic modification of T cells.

Authors:  Chiara Bonini; Malcolm K Brenner; Helen E Heslop; Richard A Morgan
Journal:  Biol Blood Marrow Transplant       Date:  2011-01       Impact factor: 5.742

2.  Evidence of a plasma-mediated "window" of immunodeficiency in rats following trauma.

Authors:  C D Mills; M D Caldwell; D S Gann
Journal:  J Clin Immunol       Date:  1989-03       Impact factor: 8.317

3.  In vivo and in vitro synergistic antitumor effect of interleukin-2-cultured tumor-bearer spleen cells and immune fresh spleen cells.

Authors:  N Kan; T Okino; M Nakanishi; K Satoh; K Ohgaki; T Tobe
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  Detection and characterization of anti-tumour effector cells in Meth-A-bearing mice treated with recombinant human interleukin 2.

Authors:  K I Naruo; S Hinuma; O Shiho; T Houkan; K Ootsu; K Tsukamoto
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

5.  The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. III. Eradication of disseminated murine chronic leukemia cells by utilizing MDP hapten-reactive helper T-cell activity.

Authors:  J Shima; T Yoshioka; H Nakajima; H Fujiwara; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

6.  Ly 1+2- suppressor T cells down-regulate the generation of Ly 1-2+ effector T cells during progressive growth of the P815 mastocytoma.

Authors:  R J North; E S Dye
Journal:  Immunology       Date:  1985-01       Impact factor: 7.397

Review 7.  Exploring the NK cell platform for cancer immunotherapy.

Authors:  Jacob A Myers; Jeffrey S Miller
Journal:  Nat Rev Clin Oncol       Date:  2020-09-15       Impact factor: 66.675

8.  Gamma-irradiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cells.

Authors:  R J North
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

9.  In vivo delayed rejection of tumors and inhibition of delayed-type hypersensitivity by HT-29 human colonic adenocarcinoma cell line.

Authors:  G J Pommier; F L Garrouste; D Bettetini; J M Culouscou; M M Remacle-Bonnet
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

10.  Immunological tolerance and tumor rejection in embryo-aggregated chimeric mice - lessons for tumor immunity.

Authors:  Alexander Y Wagner; Eric Holle; Lori Holle; Xianzhong Yu; Günter Schwamberger
Journal:  BMC Cancer       Date:  2008-12-16       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.